Cooperative Agreement HT94252420008
Award Date
9/15/24
Completion Date
9/14/28
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Cooperative Agreement
Place of Performance
Nashville, TN 37232, USA
Similar Awards
This federal Cooperative Agreement award in the amount of $1,242,250.00 was granted by the Defense Health Agency to Duke University on September 15, 2024 under the Military Medical Research and Development (CFDA 12.420) program. The award supports the Kidney Cancer Research Program Clinical Consortium, providing funding for a Duke University clinical trial site. This award extends and adds funding to an existing project, with a new ultimate completion date of September 14, 2028. The Military...
The federal Cooperative Agreement award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, provides $5,665,088.00 in funding to Vanderbilt University Medical Center (VUMC) to support the "CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING" research project. The award period runs from August 1, 2025 to July 31, 2029. The project aims to advance biomedical research that can transform healthcare for military...
This Cooperative Agreement award of $7,186,968.00 was issued on September 15, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports a Kidney Cancer Clinical Trials Consortium, including a Coordinating Center and Clinical Research Site, operated by The University of Texas M.D. Anderson Cancer Center in Houston, Texas. The funding will enable the Consortium to conduct advanced biomedical research and clinical trials...
This $1,248,000 Cooperative Agreement award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports the University of Michigan's "Phase 1/2 Clinical Trials Assessment in Kidney Cancer Therapeutics (U-MPAKT)" project. The award, effective September 15, 2024 through September 14, 2028, will fund the university's advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
This federal Project Grant award of $1,267,303.00 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Vanderbilt University Medical Center supports research to define chronic immune-related adverse events in melanoma survivors. The award period runs from August 1, 2025 to July 31, 2028. The Military Medical Research and Development program funds advanced biomedical research to transform healthcare for military service members, veterans, and the public,...
This federal Project Grant award in the amount of $962,697.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by Vanderbilt University Medical Center (VUMC) on integrin beta1, a mediator of clear cell renal cell carcinoma metastasis and growth. The research aims to advance the understanding and treatment of this form of kidney cancer, with potential applications for improving healthcare outcomes...
This federal Project Grant award of $2,399,874.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by Vanderbilt University Medical Center (VUMC) to investigate the molecular basis of post-injury syndromes and mineralization disorders. The research aims to transform healthcare for military service members, veterans, and the broader public. The 4-year award, which commenced on August 1, 2025, will fund a diverse...
The Department of Defense's Defense Health Agency awarded a $700,032 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, effective August 1, 2025 through July 31, 2029, will fund research to investigate "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in RCC." This research aims to transform healthcare for military service members, veterans, and the broader public by...
The Department of the Army Medical Command awarded an $8.2 million cooperative agreement to the University of Utah from August 1, 2022 to July 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The award will support the prevention of lethal metastatic breast cancer by identifying and eradicating clinically relevant disseminated tumor cells. A $1.5 million subaward was provided to the University Health Network in Toronto, Canada to support related research...
This Cooperative Agreement award, valued at $1,090,116.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports a clinical trial site application for the Kidney Cancer Research Consortium at the University of Texas Southwestern Medical Center (UT Southwestern), located in Dallas, Texas. The funding will allow UT Southwestern to exercise an option year and add additional funding to conduct advanced biomedical...